SAKARSAKAR Forensic Risk Analysis

Pharmaceuticals
Risk ClassStable
Market CapN/A
Primary DriverGovernance
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
0 / 100
0 QoQ
Stable
Sentinel Insight

Financial profile remains stable for now. Pressure has stabilized in governance. This indicates that forensic pressure is currently receding. No major change in risk trend.

0.0th %ile (Sector)Accel: +0 Qtrs
Updated2026-06-02
Market View
834.60.13%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

No active forensic penalties contributing.
Final Composite Risk0 / 100

Investment Risk Thesis

Historical Trend

Current risk score has declined from 60 over 13 quarters.

Expected Direction
⚠ Watch
Primary Deterioration Drivers
  • Inventory Stress
  • Working Capital Expansion
  • Low Interest Coverage
What to Watch Next Quarter
  • Inventory turnover
  • Operating profit margins
  • Working capital efficiency

Active Risk Objects (4)

CriticalHigh
Inventory Stress
📊 Earnings QualityAnnualActive for 3 Years
More Detail
Impact Weight15/15
MomentumDecaying
Last SignalQ4 FY2025
Inventory growth (57.2%) significantly outpaced revenue growth (15.1%).

"Inventory overhang is clearing. Stock levels are normalizing as sales momentum returns."

Negative FCF Streak
⚖️ Governance SignalsAnnualActive for 1 Years
More Detail
Impact Weight6/15
MomentumDecaying
Last SignalFY2024
SAKAR: Negative Free Cash Flow for last 3 consecutive years.

"Free cash flow pressure is easing as capital intensity or working capital stress recedes."

Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 2 Years
More Detail
Impact Weight10/15
MomentumDecaying
Last SignalQ4 FY2025
Working capital expansion detected: Receivable days increased by 27.7%.

"Working capital pressure is receding. Cash previously locked in operations is being released."

Low Interest Coverage
💧 Liquidity & CoverageQuarterlyActive for 1 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ4 FY2025
SAKAR: Low Interest Coverage Ratio of 2.49x in FY2025 Q4 (Threshold: 2.5x).

"The ability to cover interest is strengthening as earnings improve or debt is retired."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)5.57.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+66.0+47.0✅ RESILIENT
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
834.6(-0.13%)
1M Divergence+30.62%
1 Week+6.13%
1 Month+32.89%
6 Months+116.47%
1 Year+155.42%
2 Year+151.73%
3 Year+201.95%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in governance remain well-maintained against forensic benchmarks. Systematic scans of structural transparency and audit trails confirm the absence of material structural stress. The current structural trajectory supports a stable risk outlook.

SAKAR • MARKET STRUCTURE

Stage 2 — Advancing

The company is in a growth phase. Institutional sentiment is highly positive, supported by strong fundamentals and sustained risk reduction.

Stage Transition Prob.99%
Trend QualityStrong
Phase Progression
Phase Progression Score100%
Readiness LabelHigh (Phase Transition Imminent)
Probability of Advancing99%
CoinTree Momentum
Composite Z-Score+2.5284σ
Strong positive momentum leadership
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#62 of 2716
Top 2.28% in momentum strength
Timeframe Sparklines
1W+6.1%
1M+32.9%
6M+116.5%
Weinstein Indicators
150 DMA490.99
200 DMA454.32
150 DMA Slope+10.2651%Rising
Relative Strength+121.96%Leading
Relative Turnover (RTR)3.5388
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (19).

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
10100th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
10100th %ile
VS Sector Median (8.5)

Deterioration Timeline

2025

Inventory Stress

2025

Working Capital Expansion

2025

Inventory Stress

2024

Inventory Stress

2024

Working Capital Expansion

2024

Negative FCF Streak

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY2026254304955
FY2025179183675
FY2024157122469
FY20231381333111